Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01362660 · ClinicalTrials.gov registry record
A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7
- Enrollment target
NCT01362660: Completed study, sponsored by Pfizer.
NCT01362660 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01362660 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
Interventions
- OTHER Unintentional exposure in utero
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-06 |
What the finished NCT01362660 record still lists
NCT01362660 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Unintentional exposure in utero is the first listed.
NCT01362660 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01362660 about?
NCT01362660 is a clinical study titled "A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth". This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
What is the current status of trial NCT01362660?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2011-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01362660?
The interventions under investigation include: Unintentional exposure in utero (OTHER).
Who is sponsoring clinical trial NCT01362660?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia